Zimmer Biomet (ZBH) Stock
Key stats
- Market cap
- $19.98B
- Price / Earnings ratio
- 26.0x
- EPS (TTM)
- $3.97
- Volume
- Loading
- 52-week high
- $112.55
- 52-week low
- $79.12
- Dividend yield
- 0.89%
- Dividend amount (latest)
- $0.24
- EPS vs analyst estimate
- +1.6%Q3 FY25 · $1.90 vs $1.87
Source: third-party data provider, as of November 10, 2026
EPS estimate: analyst consensus
Compare with ZBH
Recent news

Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?
Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?
ZBH

Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
ZBH

3 of the Best Smaller-Cap Stocks to Own
3 of the Best Smaller-Cap Stocks to Own
ZBH

Should Value Investors Buy Zimmer Biomet (ZBH) Stock?
Should Value Investors Buy Zimmer Biomet (ZBH) Stock?
ZBH
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 67.31
- MACD 12/26/9
- 3.34
- EMA 9 of MACD
- 2.03
- MACD histogram
- 1.31
- SMA 50
- $95.27
- Price above SMA 50
- EMA 50
- $96.44
- Price above EMA 50
- SMA 200
- $92.14
- Price above SMA 200
- EMA 200
- $92.88
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 9, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $1.93 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?
Zimmer Biomet Gears Up to Report Q3 Earnings: What's in the Cards?
ZBH

Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
ZBH

3 of the Best Smaller-Cap Stocks to Own
3 of the Best Smaller-Cap Stocks to Own
ZBH

Should Value Investors Buy Zimmer Biomet (ZBH) Stock?
Should Value Investors Buy Zimmer Biomet (ZBH) Stock?
ZBH

Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
Zimmer Biomet (ZBH) is a Top-Ranked Value Stock: Should You Buy?
ZBH

Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
ZBH

Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?
Why Is Zimmer (ZBH) Up 1.8% Since Last Earnings Report?
ZBH

Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
Why Zimmer Biomet (ZBH) is a Top Value Stock for the Long-Term
ZBH

Is Zimmer Biomet Stock Worth Retaining in Your Portfolio Now?
Is Zimmer Biomet Stock Worth Retaining in Your Portfolio Now?
ZBH

Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
Here's Why Zimmer Biomet (ZBH) is a Strong Value Stock
ZBH
News tone: automated (AI) classification of the article's content, not a price prediction.
About Zimmer Biomet
Zimmer Biomet has been based in Warsaw since it was founded in 1927. Today, Zimmer Biomet has operations in more than 25 countries around the world and sells products in more than 100 countries. Our global team designs, manufactures and markets effective, innovative solutions that support orthopaedic surgeons and clinicians in alleviating pain and improving the quality of life for people around the world. Our musculoskeletal technologies and a wide range of related products and services make us partners to healthcare providers in more than 100 countries.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Ivan Tornos | President, CEO & Chairman of the Board | 1975 |
| Mr. Paul A. Stellato | Interim CFO, VP, Controller & Chief Accounting Officer | 1975 |
| Mr. Wilfred van Zuilen | Group President of Europe, Middle East & Africa | 1970 |
| Mr. JehanZeb Noor | Senior VP, Chief Strategy, Business Development, Innovation & Transformation Officer | 1982 |
| Mr. Kevin R. Thornal | Group President of Global Businesses & Americas | 1974 |
| Mr. Shaun Braun | Senior VP & Chief Information and Technology Officer | — |
| Dr. Jonathan M. Vigdorchik M.D. | Chief Science, Technology & Medical Affairs Officer | — |
| Mr. David M. DeMartino | Senior Vice President of Investor Relations | — |
| Mr. Chad F. Phipps J.D. | Senior VP, Chief Legal & Corporate Affairs Officer and Secretary | 1972 |
| Ms. Angela Main | Senior VP, Global Chief Compliance Officer & Associate General Counsel of Asia Pacific | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 10, 2026
Technical indicators
- RSI 14
- 67.31
- MACD 12/26/9
- 3.34
- EMA 9 of MACD
- 2.03
- MACD histogram
- 1.31
- SMA 50
- $95.27
- Price above SMA 50
- EMA 50
- $96.44
- Price above EMA 50
- SMA 200
- $92.14
- Price above SMA 200
- EMA 200
- $92.88
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 9, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $107.00
- Average
- $119.00
- High
- $130.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -10.7 | +6.1 | ||||||||||
| 2022 | -4.7 | +2.6 | +3.0 | -5.5 | -0.4 | -11.9 | +2.9 | -3.1 | -2.1 | +5.6 | +7.4 | +3.4 |
| 2023 | +0.0 | -3.1 | +5.8 | +8.1 | -8.3 | +14.3 | -3.1 | -9.9 | -6.1 | -6.3 | +10.7 | +3.2 |
| 2024 | +3.5 | -2.3 | +6.4 | -7.3 | -3.7 | -4.1 | +5.1 | +3.9 | -7.1 | -0.4 | +4.5 | -4.4 |
| 2025 | +4.8 | -3.6 | +7.4 | -8.3 | -9.5 | +0.1 | -2.6 | +17.1 | -6.2 | +1.7 | -2.4 | -5.1 |
| 2026 | -3.3 | +14.2 | -9.1 | -9.4 | -0.7 | +3.8 | +11.6 | +3.2 | -10.6 | +7.3 | +8.5 |
Corporate actions
Upcoming
No upcoming corporate actions for ZBH



